Recursion Pharmaceuticals IPO
Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery and development. The company operates one of the world's largest proprietary datasets of biological and chemical interactions to identify new therapeutic opportunities. Investors are attracted to its AI-driven approach to pharmaceutical development and potential to reduce drug discovery timelines and costs.
What We Know
Recursion Pharmaceuticals completed its IPO in April 2021, going public on NASDAQ under the ticker symbol "RXRX." The company raised approximately $436 million in its public offering, pricing shares at $18 each. The IPO was well-received initially, reflecting strong investor interest in AI-powered drug discovery companies. Since going public, Recursion has continued to advance its AI platform and drug pipeline while forming strategic partnerships with major pharmaceutical companies. Like many biotech stocks, RXRX has experienced significant volatility based on clinical trial results, partnership announcements, and broader biotech market sentiment.
Frequently Asked Questions
Has Recursion Pharmaceuticals had an IPO?
Yes, Recursion Pharmaceuticals completed its IPO in April 2021 and has been publicly traded since then. The company trades on NASDAQ under ticker "RXRX."
When is the Recursion Pharmaceuticals IPO date?
Recursion Pharmaceuticals already went public in April 2021, so there is no upcoming IPO. The company has been publicly traded for several years now.
How can I buy Recursion Pharmaceuticals stock?
You can buy Recursion Pharmaceuticals stock through any brokerage account since it trades on NASDAQ under ticker "RXRX." Shares are available during regular trading hours through standard brokers.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts